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Abstract: Background: Behavioural and psychologi-
cal symptoms in dementia (BPSD) form an important 
sub-syndrome of dementia. We assessed the frequency 
and severity of BPSD in a random sample of Hungarian 
treatment-naïve dementia patients. Furthermore, we 
examined the relationship between cognitive symptoms 
and BPSD and the pattern of BPSD in specific types of 
dementias.
Methods: Patients (n=131) were classified into 3 groups: 
Alzheimer’s (AD), vascular (VD), and mixed (MD) 
dementia. The Mini-Mental State Examination (MMSE), 
Alzheimer’s Disease Assessment Scale-Cognitive Subscale 
(ADAS-Cog) and Neuropsychiatric Inventory (NPI) neu-
ropsychological tests were employed.
Results: Mean age and MMSE score did not differ signif-
icantly among groups. BPSD was frequent (100% preva-
lence, NPI mean total Frequency score: 14.58, SD=7.55); 
abnormal motor behaviour showed the highest frequency. 
Hallucinations and delusions were related to the aetiology 
of dementia and were independent of the level of cogni-
tive deterioration, whereas irritability, sleep-wake cycle 
dysfunctions, and eating-appetite change were associated 
with cognitive deterioration and were independent from 
aetiology. Both aberrant motor behaviour and disinhibi-
tion were significantly associated with aetiology and cog-
nitive deterioration. 
Conclusions: BPSD symptoms are significant constituents 
of dementia syndromes, affecting quality of life and sub-
stantially contributing to the caregiver’s burden. Specific 
symptom patterns can be identified in different types of 
dementia.
Keywords: Alzheimer’s disease; Behaviour and psycho-
logical symptoms in dementia (BPSD); Dementia; Neuro-
cognitive disorder; Vascular dementia
Abbreviations
BPSD Behavioural and psychological symptoms in 
dementia 
AD Alzheimer’s disease
VD  vascular-dementia
MD mixed-dementia
NCD neurocognitive disorder 
MMSE Mini-Mental State Examination
NPI Neuropsychiatric Inventory
ADAS-Cog Alzheimer Disease Assessment Scale-Cognitive 
Test
IPA The International Psychiatric Association 
1  Introduction 
The 2010 WHO report drew attention to the importance of 
the increasing prevalence of dementia and to the urgent 
need for a solution to proper care of dementia patients, 
given its global burdens and dangers [1]. Based on the 
WHO report, 682 million people will probably suffer from 
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Alzheimer’s disease or other old-age dementia by 2050 
versus the present 36 million dementia patients.
Based on the DSM-IV [2], dementia is a gradually 
developing decline of cognitive functions that results in 
occupational and social dysfunctions. Beyond memory 
problems, at least one of the following symptoms must 
be present: aphasia (language disturbance), apraxia 
(impaired ability to carry out motor activities despite 
intact motor function), agnosia (failure to recognize or 
identify objects despite intact sensory function), distur-
bance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting).
 Given its possible stigmatizing effect, in DSM-5 the 
term dementia was replaced by neurocognitive disorder 
(NCD), which can be classified as mild or major and by 
its aetiology. NCD covers all types of diseases in which 
the core feature of the disease is cognitive dysfunction 
appearing as a decline from a previous level [3]. Mean-
while, the ICD-10 [4] is still in use worldwide; in that 
system, the term and the diagnostic criteria for dementia 
remain unchanged. Because Hungarian clinical practice 
follows ICD-10 and our research work had started earlier 
than the publication of DSM-5, in this paper we use the 
diagnostic category of dementia, and the term according 
to ICD-10 [4].
The two most frequent aetiological forms of demen-
tia are Alzheimer’s disease and vascular dementia; the 
occurrence of a mixed form is also common [5,6]. The 
most accepted categories for the clinical symptoms of 
dementias are cognitive, affective, and behavioural symp-
toms. The core feature of dementias are cognitive symp-
toms, whereas affective and behavioural symptoms are 
frequently reported as “behavioural and psychological 
symptoms of dementia”, or BPSD [7,8]. Differentiation, 
identification, and quantification of cognitive symptoms 
associated with dementia are more convenient for clini-
cians in everyday practice than identification and assess-
ment of BPSD symptoms [5,8]. BPSD symptoms had been 
regarded as a ‘neglected area’ of geronto-psychiatry [9]. 
The International Psychiatric Association (IPA) introduced 
the term BPSD (IPA Complete Guides to Behavioural and 
Psychological Symptoms of Dementia [10]) in 1996. BPSD 
is considered a non-disease–specific clinical syndrome, 
a sub-syndrome that consists of heterogenic psychiatric 
symptoms. The interaction of biological, psychological, 
and social factors is assumed to be behind the develop-
ment of BPSD, which consists of two subgroups of symp-
toms, psychological and behavioural. The psychological 
symptoms include delusion, hallucination, misidentifi-
cation, depression, apathy, and anxiety. The behavioural 
symptoms include irritability, agitation, aggression, wan-
dering or aberrant motor activity, disinhibition, sleep-
wake cycle disturbance, and eating disorders [11,12]. 
Regarding the relevance of BPSD symptoms, relevant lit-
erature suggests that their role in the disease-related costs 
and other economic indexes far exceeds that of cognitive 
symptoms [13]. A recently published review explored the 
results of the last 30 years’ finding in dementia research 
and emphasized the importance of BPSD symptoms [14]. 
The central role of BPSD symptoms for both the patients 
with dementia and their caregivers was clearly pointed out 
in this summary. According to the results of that review, 
at least two BPSD symptoms appeared in more than 90% 
of dementia patients, indicating connection with longer 
medical care, medicine abuse, and increased healthcare 
costs. The study suggested that the significance of BPSD 
symptoms lies in their contribution to the process in which 
primary characteristics and identity of dementia patients 
become unavoidably lost [14]. These effects of BPSD symp-
toms play an important role in caregiver distress, which 
in turn is a fundamental factor in the decision of social 
welfare placement of dementia patients [15]. The effects 
of BPSD symptoms also play a key role in the increasing 
mortality rates of those patients [8].
To our knowledge, no data on the systematic evalua-
tion of BPSD symptoms in dementia patients are available 
for Hungary. Thus, the first objective of this study was to 
evaluate the frequency and the severity of BPSD symp-
toms in a random sample of Hungarian dementia patients. 
We expected frequency and severity rates to be similar to 
those reported in the literature. The second objective of 
this study was to examine the relationship between cog-
nitive and BPSD symptoms, and the potential for using 
BPSD symptoms to differentiate clinically distinct types of 
dementias, specifically Alzheimer’s type, vascular type, 
and mixed type of dementia. We hypothesized that the 
presentation of BPSD symptoms would show a specific 
pattern in different types of dementias.
2  Methods
2.1  Study sample
Our study sample was a random, treatment-naïve sample 
of dementia patients (n=131). We included patients who 
were referred by their GP for clinical evaluation and care 
because of the suspected diagnosis of dementia, and who 
appeared for the first time in a dementia specialist prac-
tice at the Psychiatry Clinic and Neurology Clinic of the 
Clinical Centre of the University of Debrecen between Feb-
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ruary 2013 and April 2015. Further inclusion criteria were 
that patients had to live in their own apartment and not 
in a social welfare home or other nursing facility, and that 
the patient had to arrive with their relatives. Exclusion cri-
teria were ongoing treatment for depression or any other 
known mental disorder, vision, or/and hearing disorder 
that would have interfered with the completion of the tests 
in the study.
This investigation was carried out in accordance with 
the latest version of the Declaration of Helsinki. The study 
was approved by the local ethics committee and all sub-
jects provided written informed consent. 
2.2  Neuropsychological examination
After collecting demographic data and anamnesis based 
on a clinical interview, we performed a detailed neuropsy-
chological examination focusing on the cognitive deterio-
ration, BPSD symptoms, quality of life, illness intrusive-
ness, and the burden on relatives. The evaluation process 
took approximately one hour per patient. In this paper we 
focus on the results obtained from tests measuring cog-
nitive functions and BPSD symptoms. The following tests 
were applied: 
2.2.1  Mini-Mental State Examination (MMSE):
The MMSE is a brief standardized instrument that has been 
used extensively to assess individuals’ cognitive function. 
The MMSE score ranges from 0 to 30, with higher scores 
indicating better cognitive function. The MMSE assesses 
attention, orientation, language, ability to follow simple 
verbal and written commands, and immediate and short-
term recall [16].
We used MMSE because it is a widely known and 
used test for screening dementia, and it is part of the clin-
ical protocol of the assessment for dementia diagnoses. 
However, we did not include the results of the MMSE in 
our analyses: because the ADAS-Cog test (introduced in 
upcoming text) seemed to be more appropriate for eval-
uation of the cognitive functions of the patient from a 
broader perspective.
2.2.2  Alzheimer Disease Assessment Scale-Cognitive 
Test (ADAS-Cog):
This is a new rating instrument that was designed spe-
cifically to evaluate the severity of cognitive and noncog-
nitive behavioural dysfunctions and characteristics of 
patients with Alzheimer’s disease. The original version of 
the ADAS-Cog consists of 11 items, including a Word Recall 
Task, Naming Objects and Fingers, Following Commands, 
Constructional Praxis, Ideational Praxis, Orientation, 
Word Recognition Task, Remembering Test Directions, 
Spoken Language, Comprehension, and Word-finding Dif-
ficulty. The ADAS-Cog score can vary between 0 and 70 
(the greater the dysfunction, the higher the score). A usual 
score for someone who does not have any type of demen-
tia is five [17,18].
2.2.3  Neuropsychiatric Inventory (NPI): 
The NPI was developed by Cummings et al. (1994) [19] 
to assess dementia-related behavioural symptoms. The 
NPI originally examined 10 sub-domains of behavioural 
functioning: delusions, hallucinations, agitation/aggres-
sion, dysphoria, anxiety, euphoria, apathy, disinhibi-
tion, irritability/lability, and aberrant motor activity. Two 
more sub-domains have been added since its develop-
ment: night-time behavioural disturbances, appetite and 
eating abnormalities. This wide variety of domains means 
that, unlike other dementia measures, the NPI is able to 
screen for BPSD symptoms in multiple types of dementia. 
The NPI is assessed based on caregiver report. A screen-
ing question is asked about each sub-domain. If the 
responses to these questions indicate that the patient has 
problems with the behaviour addressed by the particular 
sub-domain in question, the caregiver is then asked all 
the questions only about that domain. The NPI rates the 
frequency of the symptoms on a 4-point scale, the severity 
of the symptoms on a 3-point scale, and the distress the 
symptom causes for the caregiver on a 5-point scale. The 
maximum score is 144 [19].
2.3  Diagnosis of dementia: Assigning 
patients into diagnostic groups
Patients who received the clinical diagnosis of dementia 
in the outpatient clinic were further divided into 3 groups: 
Alzheimer’s-disease (AD), vascular-dementia (VD), and 
mixed-dementia (MD).
The diagnosis of dementia and assigning diagnosed 
patients to three different subtype groups were based on 
a routine clinical decision protocol that included detailed 
anamnesis, neuropsychiatric and somatic examination, 
laboratory tests, CT and/or MRI scans.
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This protocol followed the usual clinical practice of 
the evaluation and diagnosis of dementia in the partici-
pating specialist centres.
2.4  Statistical analysis
For data management and analysis, we used Stata (Stat-
aCorp. 2009. Stata Statistical Software: Release 11. College 
Station, TX StataC) statistical program. We considered 
p<0.05 as indicating statistical significance. For data anal-
ysis we applied descriptive statistics for presenting the 
main characteristics of the sample, calculating means 
and standard deviations. For inferential analysis we 
applied Pearson’s chi-squared test and Fisher’s exact test 
for examining between-group differences in categorical 
variables, whereas for examining associations between 
categorical and continuous variables we applied either 
ANOVA, or the Kruskal-Wallis test based on the normal 
versus non-normal distribution of the data. 
3  Results
Altogether 131 patients were included in the study; all 
were Caucasians. Mean age was 77 years (SD=8.3). Fif-
ty-five patients were assigned to the AD group, 33 patients 
were assigned to the VD group, and 43 patients were 
assigned to the MD group. There were no significant dif-
ferences across groups regarding gender distribution and 
age. Demographic data is summarized in Table 1. 
3.1  Results of the evaluation of cognitive 
functions
Cognitive functions were evaluated with the MMSE and 
the ADAS-Cog. Mean score was 19 (SD=5.69) for the MMSE, 
and 39.47 (SD=14.18 range 8–66) for the ADAS-Cog. There 
was no significant difference between the diagnostic 
groups regarding severity of cognitive deterioration as 
measured by the two tests. Table 2 shows the results of the 
cognitive measures in the different study groups.
3.2  Results of the evaluation of BPSD 
symptoms 
BPSD symptoms were measured using the NPI scale. We 
compared the study groups on mean total scores, and fre-
quency and severity of the individual symptoms. 
The mean NPI total score was 44.09 (SD=22.73; range 
11–103), mean total Frequency score was 14.58 (SD=7.55; 
range 3–36), and mean total Severity score was 12.87 
(SD=6.42; range 3–29). With respect to individual symp-
toms, based on the frequency scores, abnormal motor 
behaviours (2.79 [SD=1.2]), depression (1.86, [SD=1.2]), 
agitation (1.77 [SD=1.2]), and eating-appetite change (1.4 
[SD=1.3]) were the most frequent in the total sample.
Table 2.  Results of the assessment of cognitive func-
tions and results of evaluation of BPSD symptoms in the 
different study groups
There were no significant differences across study 
groups in the mean total score, mean frequency score and 
mean severity score of NPI. 
We found significant differences across study groups 
with regard to the frequency of individual BPSD symp-
toms. Specifically, frequency of delusions was signifi-
Table 1: Demographic data of the study sample
Study group Sample size
n (%)
Age (years)
Mean (SD)
Gender
male (%)
Alzheimer 55 (41.9) 75.1 (9.72) 27.27
Vascular 33 (25.2) 76.8 (7.59) 39.39
Mixed 43 (32.8) 79.5 (6.12) 46.51
Total 131 (100) 77 (8.31) 36.64
Table 2. Results of the assessment of cognitive functions and results of evaluation of BPSD symptoms in the different study groups
Alzheimer’s Vascular Mixed p-value+
MMSE Mean (SD) 16.72 (5.36) 17.35 (4.51) 18.102 (4.75) 0.4155
ADAS-Cog Mean (SD) 38.75 (13.8) 41.6 (14.66) 38.73 (14.46) 0.6943
NPI total score Mean (SD) 45.21 (23.82) 42.63 (18.87) 43.76 (24.38) 0.87
NPI frequency Mean (SD) 14.85 (7.87) 14.3 (6.4) 14.4 (8.09) 0.93
NPI severity Mean (SD) 13.29 (6.87) 12.27 (5.36) 12.79 (6.66) 0.77
+: p-values based on ANOVA test
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cantly higher in both the MD and AD groups compared 
with the VD group. Hallucinations were the most frequent 
in the AD group, and the least frequent in the VD group, 
with significant differences across all groups. Between-
group differences were significant also for the uninhib-
itedness symptom, showing the highest frequency in 
the VD group and the lowest frequency in the AD group, 
although this symptom was in general the third-less-fre-
quent symptom among all the BPSD symptoms measured 
in the test. Abnormal motor behaviour, however, showed 
the highest prevalence in all study groups from the meas-
ured BPSD symptoms and also showed significant differ-
ences between the study groups. Specifically, abnormal 
motor behaviour was more frequent in both the AD and 
the MD group compared with the VD group.
Considering the severity of symptoms, the most 
severe symptoms turned out to be abnormal motor behav-
iours (mean 2.32 [SD=1.04]), agitation (mean 1.61 [SD=1.1]), 
depression (mean 1.59 [SD=0.99]), and eating-appetite 
change (mean 1.2 [SD=1.1]), (Table 3).
Regarding the severity of the individual BPSD symp-
toms, we found significant differences among the groups. 
Specifically, hallucinations were the most severe in the AD 
group and the least severe in the VD group; agitation was 
significantly more severe in the VD group compared with 
the MD group; anxiety was significantly more severe in the 
AD group compared with the VD group; uninhibitedness 
was significantly more severe in the VD group compared 
with the AD group (Table 3).
3.3  Results of analysing the relationship 
between BPSD symptoms and cognitive 
functions.
We examined the relationship between the level of cogni-
tive deterioration as measured by the ADAS-Cog, and the 
frequency and severity of BPSD symptoms as measured by 
the NPI test. 
NPI total score, frequency total score, and sever-
ity total score were significantly associated with the 
ADAS-Cog total score (p < 0.0001, p < 0.0001 based on 
Kruskal-Wallis test, and p= 0.0002 based on ANOVA).
Individual BPSD symptoms also showed association 
with the ADAS-Cog score, specifically apathy, irritability, 
sleep-wake cycle dysfunctions, eating-appetite change, 
aberrant motor behaviour, and disinhibition. Results indi-
cated that lower level of cognitive functions were associ-
ated with higher frequency and more severe presentation 
of these BPSD symptoms. Please see Table 3 and Figures 
1-3 for more details.
Figure 1. Association between cognitive functions 
(ADAS-Cog score) and BPSD symptoms (based on NPI total 
score). Analyses were based on the Kruskal-Wallis test, or 
ANOVA, depending on the original normal vs non-normal 
distribution of the data.
Figure 2. Association between cognitive functions 
(ADAS-Cog score) and BPSD symptoms (based on in 
NPI frequency total score). Analyses were based on the 
Kruskal-Wallis test, or ANOVA, depending on the original 
normal vs non-normal distribution of the data. 
Figure 3. Association between cognitive functions 
(ADAS-Cog score) and BPSD symptoms (based on in 
NPI severity total score). Analyses were based on the 
Kruskal-Wallis test, or ANOVA, depending on the original 
normal vs non-normal distribution of the data.
4  Discussion
In this study, we examined the frequency and severity of 
BPSD symptoms in a random sample of treatment-naïve 
Hungarian dementia patients. Our sample on average 
showed medium severity of dementia (Mean ADAS-Cog 
score 39.46 points).  Demographical data (gender distri-
bution: 36.64% male, mean age: 77 years) of our sample 
was comparable to that of previously examined samples 
reported in the literature [20]. 
Regarding the frequency of BPSD symptoms, pub-
lished data shows extreme differences in various research 
settings and in samples of dementia patients with differ-
ent levels of severity [21]. In the case of medium-sever-
ity dementia, frequency of BPSD symptoms of different 
levels of severity was reported between 20% and 90% 
[22]. In our study, the prevalence of BPSD symptoms was 
100%, meaning that there was no patient in our sample 
without at least one BPSD symptom [23]. The reason for 
this exceptionally high prevalence rate of BPSD symp-
toms may be that in our study the evaluation of the BPSD 
symptoms was thorough, was based on a very detailed 
BPSD specific interview, and that the questions were 
directed to the patient’s primary caregiver. In contrast, 
most of the studies reporting data on the presence of 
BPSD symptoms in patients used either less specific and 
less detailed measurements, or a different information 
source (self-evaluation, doctors rating, etc.) [24,25,26]. 
Furthermore, some studies evaluated only certain parts of 
the BPSD symptoms or did not target the thorough evalua-
tion of the BPSD symptoms themselves but had a different 
focus (e.g., pharmacotherapy studies) [27,28].
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Based on our results, the most frequent BPSD symp-
toms were aberrant motor behaviour (69.31%), depression 
(46.21%), agitation (44.12%), appetite and eating change 
(35.03%), anxiety (30.11%), sleep and night-time behav-
iour (28.78%), delusion (28.77%), irritability (24.62%), 
and hallucination (22.72%), whereas apathy, disinhibi-
tion, and euphoria were present in less than 10% of cases. 
These findings are different from previously reported 
Table 3: Associations between NPI item scores and severity of cognitive deterioration and dementia aetiology
NPI scores ADAS-Cog 3 diagnostic 
groups
Mixed vs  
Vascular+++
Alzheimer’s vs 
Vascular+++
Alzheimer’s vs 
Mixed+++
frequency total score p<0.0001+ p=0.9394++ - - -
delusion: frequency p=0.0526+ p=0.038+++ p=0.027 p=0.351 p=0.061
hallucinations: frequency p=0.1184+ p<0.001+++ p=0.218 p=0.015 p<0.001
agitation: frequency p=0.9609++ p=0.091+++ p=0.236 p=0.038 p=0.266
depression: frequency p=0.2107+ p=0.116+++ p=0.089 p=0.018 p=0.991
anxiety: frequency p=0.6039++ p=0.606+++ p=0.495 p=0.556 p=0.514
euphoria: frequency p=0.9513+ p=0.060+++ p=0.071 p=0.045 p=0.573
apathy: frequency p=0.0096+ p=0.122+++ p=0.655 p=0.074 p=0.123
disinhibition: frequency p<0.0001+ p=0.032+++ p=0.329 p=0.005 p=0.259
irritability: frequency p=0.0003+ p=0.433+++ p=0.743 p=0.468 p=0.211
aberrant motor behaviour: 
frequency
p=0.0102+ p=0.005+++ p=0.004 p=0.007 p=0.350
sleep and night-time behav-
iour: frequency
p=0.0015+ p=0.930+++ p=0.673 p=0.814 p=0.919
appetite and eating 
changes: frequency
p=0.0027+ p=0.123+++ p=0.313 p=0.185 p=0.077
severity total score p=0.0002++ p=0.7706++ - - -
delusion: severity p=0.0954++ p=0.086+++ p=0.082 p=0.028 p=0.735
hallucinations: severity p=0.1572+ p=0.000+++ p=0.004 p=0.000 p=0.016
agitation: severity p=0.9764++ p=0.047+++ p=0.124 p=0.268 p=0.029
depression: severity p=0.2995+ p=0.083+++ p=0.140 p=0.013 p=0.850
anxiety: severity p=0.9356++ p=0.032+++ p=0.617 p=0.169 p=0.007
euphoria: severity p=0.9513+ p=0.060+++ p=0.071 p=0.045 p=0.573
apathy: severity p=0.0074+ p=0.161+++ p=0.151 p=0.054 p=0.790
disinhibition: severity p<0.0001+ p=0.009+++ p=0.084 p=0.001 p=0.425
irritability: severity p<0.0001+ p=0.568+++ p=0.449 p=0.308 p=0.718
aberrant motor behaviour: 
severity
p=0.0010+ p=0.084+++ p=0.143 p=0.033 p=0.445
sleep and night-time behav-
iour: severity
p=0.0001+ p=0,221+++ p=0.228 p=0.046 p=0.830
appetite and eating 
changes: severity
p=0.0010+ p=0.449+++ p=0.772 p=0.230 p=0.375
+: p-values based on Kruskal-Wallis test 
++: p-values based on ANOVA test
+++: p-values based on Fisher’s exact test
 Red colour highlights significant p-values for easier review of the data presented
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findings in the literature regarding the prevalence of 
mood disorder symptoms and the possibly related appe-
tite and sleep-wake cycle symptoms. In our study, these 
BPSD symptoms are less frequent compared to previously 
reported data [29, 30, 31]. A reason for this difference may 
be that in our study patients with previously diagnosed 
mental disorders – including major depression – were 
excluded to avoid overlapping symptom detection (e.g., 
affective symptoms being present not due to BPSD but 
because of a pre-existing mental condition). 
Our findings suggest that BPSD as a symptom group 
requires medical attention, because in line with previous 
data [13], the most frequent symptoms in our sample were 
those that had been already reported as important risk 
factors for higher mortality rates and early nursing home 
placement. 
As the second objective of this study, we examined 
whether a specific BPSD symptom pattern existed in dif-
ferent types of dementias. Our results showed that hal-
lucination, abnormal motor behaviour, and anxiety were 
significantly more frequent in AD and MD compared with 
VD; hallucinations and delusions were also significantly 
more severe in AD and MD compared with VD. Disinhibi-
tion, however, was significantly more frequent and more 
severe, and agitation was significantly more severe among 
VD patients compared to those with AD and MD.
In a study that included more than 2000 demented 
patients from the 4 most frequent etiological groups, 
similar results were reported [32]. Specifically, in vascular 
dementia, mood-related BPSD symptoms were prominent, 
whereas in Alzheimer dementia, the psychotic-type BPSD 
symptoms were rather prevalent. Brain SPECT confirmed 
frontotemporal-perfusion abnormality in Alzheimer 
patients with BPSD symptoms. Based on post-mortem 
data, more neurofibrillary tangles were found in the brain 
of patients previously showing psychotic symptoms like 
hallucinations or delusions. This finding indeed connects 
the presence of these BPSD symptoms to Alzheimer-spe-
cific neuropathology. Thus, psychotic symptoms are less 
likely to be taken as generalizable BPSD symptoms in 
dementia [9,33]. The presence of mood disorders such as 
apathy, irritability, agitation, depression, distress, and 
euphoria, as well as delusions and disinhibition have 
been, however, emphasized in vascular dementia in pre-
vious reports [34,35]. 
Our results indicated that not only the dementia 
subtype, but also the level of cognitive deterioration was 
associated with the frequency and the severity of certain 
BPSD symptoms. Worse cognitive functions were related 
to higher frequency and greater severity of apathy, irri-
tability, sleep-wake cycle dysfunctions, eating-appetite 
change, aberrant motor behaviour, and disinhibition.
Interestingly, our findings showed that hallucinations 
and delusions were related to the aetiology of dementia 
and were independent of the level of cognitive deteriora-
tion, whereas apathy, irritability, sleep-wake cycle dys-
functions, and eating-appetite change were associated 
with cognitive deterioration and were independent of 
aetiology. Although relevant scientific research focuses 
Figure 1: Association between cognitive functions (ADAS-Cog score) 
and BPSD symptoms (based on NPI total score).
Figure 2: Association between cognitive functions (ADAS-Cog score) 
and BPSD symptoms (based on NPI frequency total score). 
Figure 3: Association between cognitive functions (ADAS-Cog score) 
and BPSD symptoms (based on NPI severity total score). 
Unauthenticated
Download Date | 5/31/19 7:09 AM
314    Réka Majer et al. 
rather on identifying factors that may contribute to the 
more accurate clinical diagnosis regarding the aetiology 
of dementia to provide more specific therapeutic interven-
tions, our findings point toward another important aspect 
of dementia. Specifically, cognitive deterioration is a 
leading symptom of dementia, but at the same time there 
is a broader symptomatology to be taken into considera-
tion over the course of the illness that is connected to the 
gradual structural deterioration of the brain that results in 
declining functionality. Identifying those BPSD symptoms 
that become more frequent and severe along with the cog-
nitive deterioration helps us understand the nature of the 
structural damage appearing over time during the course 
of the illness on one hand, and on the other hand, it helps 
us to exclude observable symptoms from aetiology-based 
clinical decisions or research targets. 
We found two symptoms, aberrant motor behaviour 
and disinhibition, that were both associated with aetiol-
ogy and cognitive deterioration. Aberrant motor behav-
iour was the most frequent BPSD symptom, so it might 
be an early appearing BPSD symptom, especially in AD, 
whereas disinhibition was one of the less frequent BPSD 
symptoms in this sample, thus it may appear in later 
phases (in severe cases – our sample was on average 
medium severity), and is typical especially for VD. These 
findings are in line with previous findings [14,32].
4.1  Limitations of the study
Our results have to be interpreted in light of certain lim-
itations. This study was explorative in nature and thus, 
conclusions have to be drawn cautiously. Second, caus-
ative relationships cannot be judged because this was a 
cross sectional study. Third, sample sizes in the examined 
subgroups were small; that also prevents us from drawing 
firm conclusions from our results. Fourth, there was no 
neuropathological confirmation of the dementia subtype.
Using a randomly selected sample, however, brought 
a natural heterogeneity to the whole sample. All these fea-
tures of the study allowed us to observe general trends in 
dementia patients with regard to the examined associa-
tions. These observed trends may help clinicians in their 
everyday practice and may suggest future research direc-
tions for more specific and rigorously designed experi-
ments.
5  Conclusions
Our results, based on this explorative study on a randomly 
selected sample of treatment naïve dementia patients, 
supported previous findings in the literature concerning 
high prevalence of BPSD symptoms in dementia patients. 
This was the first systematic study collecting information 
on BPSD symptoms among Hungarian dementia patients. 
We identified specific differences in the presentation of 
BPSD symptoms in clinically distinct types of dementia, 
and a significant relationship between the level of cog-
nitive deterioration and the presentation of BPSD symp-
toms. Although our findings are preliminary and future 
studies would be essential to understand these associa-
tions in detail, a possible clinical pattern of non-cognitive, 
behavioural, and psychological symptoms is suggested in 
different types of dementia. Such a pattern may aid clini-
cians in the diagnosis, as well as in informing and edu-
cating patients and relatives on expected outcome and 
course of illness. A more predictable course of illness 
may, in turn, help caregivers prepare practically and psy-
chologically to the challenge they are facing in the long 
term, and thus, may significantly increase the nursing 
time at home instead of early placement of the patient in 
a nursing home.
The consistently reported high prevalence of BPSD 
symptoms in dementia patients, together with our current 
findings, emphasizes the clinical importance of this 
sub-syndrome of dementia that requires further study and 
clinical attention.
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